Clinical Scorecard: Could Wegovy Raise Optic Nerve Risk?
At a Glance
| Category | Detail |
|---|---|
| Condition | Ischemic Optic Neuropathy (ION) |
| Key Mechanisms | Potential dose-dependent effects on optic nerve perfusion, intravascular volume contraction, hypotension, or autonomic instability. |
| Target Population | Patients using semaglutide formulations, particularly higher-dose Wegovy. |
| Care Setting | Outpatient settings where GLP-1 receptor agonists are prescribed. |
Key Highlights
- Wegovy (2.4 mg) has a 4.7-fold higher odds of ION compared to Ozempic (1 mg).
- Men have 3.3-fold higher odds of reported ION than women.
- No ION reports were identified with oral semaglutide (Rybelsus).
- Tirzepatide formulations showed no detectable ION reporting signal.
- The analysis is based on over 30 million FAERS reports.
Guideline-Based Recommendations
Diagnosis
- Monitor for symptoms of ION in patients prescribed semaglutide.
Management
- Consider individualized GLP-1 therapy based on risk factors.
Monitoring & Follow-up
- Conduct longitudinal pharmacoepidemiologic studies for better risk stratification.
Risks
- Increased risk of ION with higher-dose semaglutide formulations.
Patient & Prescribing Data
Patients with obesity or type 2 diabetes prescribed semaglutide.
Wegovy has a stronger reporting signal for ION compared to Ozempic.
Clinical Best Practices
- Evaluate patient history for risk factors before prescribing higher doses of semaglutide.
- Educate patients on potential visual symptoms and the importance of reporting them.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
